Stockscreener 앱 받기
4.31
4.36%
0.18
시간 외 거래:
4.31
전일 마감가:
$4.13
열려 있는:
$4.19
하루 거래량:
699.58K
Relative Volume:
0.72
시가총액:
$293.81M
수익:
-
순이익/손실:
$-27.03M
주가수익비율:
-7.6964
EPS:
-0.56
순현금흐름:
$-23.97M
1주 성능:
+5.12%
1개월 성능:
+8.84%
6개월 성능:
-17.27%
1년 성능:
+20.06%
1일 변동 폭
$4.12
$4.67
1주일 범위
$4.051
$4.67
52주 변동 폭
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
명칭
Corvus Pharmaceuticals Inc
전화
(650) 900-4520
주소
863 MITTEN ROAD, BURLINGAME, CA
CRVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
4.31 | 321.57M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-02 | 개시 | H.C. Wainwright | Buy |
| 2023-08-18 | 개시 | Oppenheimer | Outperform |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-05-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-10 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-05-29 | 개시 | ROTH Capital | Buy |
| 2017-08-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 개시 | Credit Suisse | Outperform |
| 2016-04-18 | 개시 | Guggenheim | Buy |
모두보기
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
Is Corvus Pharmaceuticals Inc. stock ready for a breakoutTrend Analysis for Safer Market Entries - Newser
Long term hold vs stop loss in Corvus Pharmaceuticals Inc.Strategy Builder for Growth Focused Traders - Newser
What makes Corvus Pharmaceuticals Inc. stock price move sharplyShort Term Momentum Based Trading Strategy - Newser
Is Now a Good Time to Reenter Corvus Pharmaceuticals Inc.Scalable Portfolio Growth Suggestions Released - beatles.ru
Corvus (CRVS) Q2 Loss Beats Estimates - AOL.com
Advanced analytics toolkit walkthrough for Corvus Pharmaceuticals Inc.Pattern Breakout Prediction for Short Term - Newser
How to forecast Corvus Pharmaceuticals Inc. trends using time seriesFree Entry Zone Strategy for Consistent Profit - Newser
Real time pattern detection on Corvus Pharmaceuticals Inc. stockTechnical Insight Guide for Safer Trades - Newser
What to expect from Corvus Pharmaceuticals Inc. in the next 30 daysFree Short Term Buy List With Stop Protection - Newser
Corvus plans Phase II trial for soquelitinib in atopic dermatitis, targeting 200 patients with 12-week treatment window - MSN
Traders Watching For Reversal Pattern in Corvus Pharmaceuticals Inc.AI Trading Suggestions With Accuracy Focus Released - metal.it
Can volume confirm reversal in Corvus Pharmaceuticals Inc.Portfolio Building Plan and Summary Guide - Newser
Sentiment analysis tools applied to Corvus Pharmaceuticals Inc.Free Trend Analysis for Safer Trades - Newser
Custom strategy builders for tracking Corvus Pharmaceuticals Inc.Daily Breakout List with Smart Filters - Newser
Price action breakdown for Corvus Pharmaceuticals Inc.Predictive Screener for Daily Trade Watch - Newser
What recovery options are there for Corvus Pharmaceuticals Inc.Real Chart Based Opportunity Identification - Newser
Momentum divergence signals in Corvus Pharmaceuticals Inc. chartTechnical Trade Plan with Entry Checklist - Newser
Transcript : Corvus Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Is it time to cut losses on Corvus Pharmaceuticals Inc.Free Stock Screener With Smart Filters - Newser
Can technical indicators confirm Corvus Pharmaceuticals Inc.’s reversalFree Short Term Setup With Predictive Chart - Newser
Earnings call transcript: Corvus Pharmaceuticals’ Q2 2025 results show EPS beat By Investing.com - Investing.com South Africa
Earnings call transcript: Corvus Pharmaceuticals’ Q2 2025 results show EPS beat - Investing.com
Corvus Pharmaceuticals Inc (CRVS) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Published on: 2025-08-08 00:04:14 - Newser
Corvus Pharmaceuticals Reports Q2 2025 Progress and Financials - TipRanks
Corvus Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Institutional scanner results for Corvus Pharmaceuticals Inc.Free Reliable Alerts for Daily Stock Movers - Newser
Corvus: Q2 Earnings Snapshot - San Francisco Chronicle
Corvus Reports Breakthrough: New Atopic Dermatitis Drug Shows Powerful 65% Disease Reduction in Phase 1 Trial - Stock Titan
Does Corvus Pharmaceuticals Inc. qualify in momentum factor screeningTrade Setup Builder with Custom Alerts - Newser
Why Corvus Pharmaceuticals Inc. stock attracts strong analyst attentionVolume Based Swing Signal Prediction Map - Newser
New Product Launches: Will They Boost Corvus Pharmaceuticals Inc. Stock in 2025Volume Spike Detection for Early Breakouts - Newser
Can swing trading help recover from Corvus Pharmaceuticals Inc. lossesLong Term Stock Growth Plan Suggestions - Newser
Corvus Pharmaceuticals Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Corvus Pharmaceuticals Ownership: Retail Investors Dominate with 48% Stake, Institutions Hold 33% - AInvest
Corvus Pharmaceuticals Inc. Breaks Losing Streak — Is the Trend ReversingPortfolio Diversification Stock Ideas From Experts - beatles.ru
How Corvus Pharmaceuticals Inc. stock performs during market volatilityFree Safe Entry Stock Watch Suggestions - Newser
Corvus Pharmaceuticals Inc (CRVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):